The Russian pharmaceutical company “Geropharm” (ranked among the top twenty in the country) has registered an anti-diabetic drug called semaglutide [mimics the hormone that regulates glucose levels - note www1. ru] under the name “Semavic”. The registration documents were obtained on October 6th. This is reported by “Kommersant” citing a statement by the company.
The production of the “Semavic” drug will help solve the problem of a potential shortage of semaglutide against the backdrop of the withdrawal from Russia of the Danish company Novo Nordisk, which produced “Ozempik”. According to the Russian health regulator, the foreign manufacturer planned to abandon the supply of semaglutide to the Russian market by the end of 2023.
“Ozempik” is used in many countries around the world for the treatment of type 2 diabetes in case of insulin deficiency. As reported by DSM Group, from January to August 2023, more than 2 billion rubles of semaglutide was sold in Russian pharmacies.
The price of “Ozempik” was regulated in Russia, it should not have exceeded 5.8 thousand rubles per dose. “Geropharm” announced a maximum cost for its product at the level of 6 thousand rubles. It is known that a patient with diabetes requires one dose per week.